Postmarketing Research and Surveillance: Issues and Challenges.
作者信息
Resnik David B
出版信息
Monitor (Assoc Clin Pharmacol). 2008 Apr;22(2):45-48.
Abstract
摘要
相似文献
1
Postmarketing Research and Surveillance: Issues and Challenges.
Monitor (Assoc Clin Pharmacol). 2008 Apr;22(2):45-48.
2
Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
J Intern Med. 2014 Jun;275(6):551-61. doi: 10.1111/joim.12159.
3
The ethical issues of the postmarketing surveillance of drug teratogenicity in Hungary.
Pharmacoepidemiol Drug Saf. 2001 Dec;10(7):635-9. doi: 10.1002/pds.635.
4
Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
Pharmacogenomics. 2003 Sep;4(5):647-55. doi: 10.1517/phgs.4.5.647.23793.
5
Postmarketing surveillance: curriculum for the clinical pharmacologist. Part I: Postmarketing surveillance within the continuum of the drug approval process.
J Clin Pharmacol. 1993 Oct;33(10):904-11. doi: 10.1002/j.1552-4604.1993.tb01920.x.
6
Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance.
Invest Radiol. 2011 Nov;46(11):663-71. doi: 10.1097/RLI.0b013e3182218dc3.
7
Record linkage studies for postmarketing drug surveillance: data quality and validity considerations.
Drug Intell Clin Pharm. 1988 Feb;22(2):157-61. doi: 10.1177/106002808802200216.
8
Endovascular Aneurysm Repair Devices as a Use Case for Postmarketing Surveillance of Medical Devices.
JAMA Intern Med. 2023 Oct 1;183(10):1090-1097. doi: 10.1001/jamainternmed.2023.3562.
9
[Tolerance and safety of tramadol use. Results of international studies and data from drug surveillance].
Drugs. 1997;53 Suppl 2:50-62. doi: 10.2165/00003495-199700532-00010.
10
[A discussion of key issues on postmarketing reevaluation of Chinese medicine].
Zhongguo Zhong Yao Za Zhi. 2010 Jun;35(11):1494-7.
引用本文的文献
1
Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics.
Sci Transl Med. 2020 Jun 24;12(549). doi: 10.1126/scitranslmed.aay6570.
本文引用的文献
1
Beyond post-marketing research and MedWatch: Long-term studies of drug risks.
Drug Des Devel Ther. 2007 Oct 1;1:1-5. doi: 10.2147/dddt.s2352.
2
US Senate passes FDA Revitalization Act.
CMAJ. 2007 Jul 3;177(1):23. doi: 10.1503/cmaj.070779.
3
Class of antiretroviral drugs and the risk of myocardial infarction.
N Engl J Med. 2007 Apr 26;356(17):1723-35. doi: 10.1056/NEJMoa062744.
4
Challenges in using observational studies to evaluate adverse effects of treatment.
N Engl J Med. 2007 Apr 26;356(17):1705-7. doi: 10.1056/NEJMp078038.
5
How the US drug safety system should be changed.
JAMA. 2006 May 3;295(17):2072-5. doi: 10.1001/jama.295.17.2072.
6
Reform of drug regulation--beyond an independent drug-safety board.
N Engl J Med. 2006 Jan 12;354(2):194-201. doi: 10.1056/NEJMsb053432.
7
Drug safety. Gaps in the safety net.
Science. 2005 Jan 14;307(5707):196-8. doi: 10.1126/science.307.5707.196.
8
Postmarketing surveillance--lack of vigilance, lack of trust.
JAMA. 2004 Dec 1;292(21):2647-50. doi: 10.1001/jama.292.21.2647. Epub 2004 Nov 22.
Zotero 插件